Endocyte Competitors, Revenue, Alternatives and Pricing

Claim your profile


West Lafayette, IN USA
Total Funding:$160M
Lead Investor(s):Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc

Estimated Revenue & Financials

  • Endocyte's estimated annual revenue is currently $19.3M per year.(?)
  • Endocyte received $101.8M in venture funding in April 2014.
  • Endocyte's estimated revenue per employee is $201,000
  • Endocyte's total funding is $160M.

Employee Data

  • Endocyte has 96 Employees.(?)
  • Endocyte grew their employee count by 19% last year.
  • Endocyte currently has 1 job openings.

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.